<DOC>
	<DOCNO>NCT01140776</DOCNO>
	<brief_summary>The study determine sensitivity , specificity , negative predictive value positive predictive value OSNA Breast Cancer System patient receive Sentinel Lymph Node biopsy receive neoadjuvant hormonal/chemotherapy compare permanent section Hematoxylin Eosin ( H &amp; E ) Immuno-histochemistry ( IHC ) staining .</brief_summary>
	<brief_title>Clinical Evaluation OSNA Breast Cancer System Breast Cancer Patients Receiving Neoadjuvant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<criteria>Male female 18 year age old Diagnosed pre‐surgically T1‐T3 T4 non‐inflammatory breast cancer , clinically node positive node negative upon clinical examination Scheduled SLN biopsy receive neoadjuvant hormonal chemotherapy Subjects ( subject ' legal representative ) read , understood ( best ability ) sign informed consent form . Pregnant subject , confirm interview either subject treating physician Subjects previously diagnose invasive cancer . Subjects skin cancer ( basal cell squamous cell carcinoma ) may include , except subject diagnose melanoma Participation neoadjuvant protocol specifically require SLN biopsy prior administration neoadjuvant chemotherapy hormonal therapy Subjects judge inappropriate candidate medical care provider ( e.g. , surgeon , oncologist pathologist ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>metastasis</keyword>
	<keyword>molecular pathology</keyword>
</DOC>